Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:

NCT ID: NCT02546791 Completed - Leukemia Clinical Trials

Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study

PASS
Start date: July 22, 2015
Phase: N/A
Study type: Observational

This is a retrospective, multicenter, descriptive analysis of patients with a diagnosis of chronic myeloid leukemia, treated with dasatinib for at least 45 days. The study will include 100 patients treated in different public centers in the Mexican Republic.

NCT ID: NCT02546284 Completed - Clinical trials for Chronic Myelomonocytic Leukemia (CMML)

Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)

Start date: July 2016
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, repeat-dose, Phase 1 Dose Escalation Study to evaluate safety, pharmacokinetics, and clinical activity.

NCT ID: NCT02544789 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia

Start date: June 2009
Phase: Phase 2
Study type: Interventional

Outcomes for children with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) are dismal. Therefore, the investigators performed this multicenter, phase II study to evaluate the efficacy and , safety and pharmacokinetic of clofarabine in Chinese pediatric patients with R/R ALL

NCT ID: NCT02544438 Completed - Clinical trials for Acute Myeloid Leukemia

Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

BSTPHASE1-01
Start date: September 2015
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/IIa, open-label, uncontrolled study to evaluate the safety and efficacy of Astarabine (BST-236) as single agent in patients with refractory or relapsed Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) disease

NCT ID: NCT02543879 Completed - Clinical trials for Acute Myeloid Leukemia

Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies

Start date: September 2015
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, dose-escalation Phase 1/1b study in patients with acute myelogenous leukemia (AML)/MDS or non-Hodgkin Lymphoma (NHL), intended to investigate safety, pharmacokinetics, and the pharmacodynamic effects of FT-1101 administered via one or more intermittent dosing schedules alone and in combination with azacitidine. Once the MTD has been established for a treatment cohort, up to 20 additional patients may be enrolled in up to 4 expansion cohorts each of select populations of patients with either AML/MDS or NHL at the recommended dose for future studies to confirm safety.

NCT ID: NCT02538965 Completed - Leukemia, Myeloid Clinical Trials

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Start date: November 19, 2015
Phase: Phase 2
Study type: Interventional

To determine the activity of lenalidomide in the treatment of pediatric subjects with relapsed/refractory acute myeloid leukemia (AML) (with second or greater relapse or refractory to at least 2 prior induction attempts) measured by morphological complete response defined as either a CR or CRi within the first 4 cycles of treatment.

NCT ID: NCT02535286 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

Start date: September 18, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL or Richter's Transformation.

NCT ID: NCT02533401 Completed - Clinical trials for Lymphocytic Leukemia, Chronic

A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)

Start date: February 2006
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of rituximab in combination with chemotherapy in participants with B-cell CLL. The anticipated time on study treatment is 6 months, and the target sample size is 30 individuals.

NCT ID: NCT02532231 Completed - Clinical trials for Adult Acute Myeloid Leukemia in Remission

Nivolumab in AML in Remission at High Risk for Relapse

Start date: October 19, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nivolumab works in treating patients with acute myeloid leukemia that has decreased or disappeared but may still be in the body (remission), and is at high risk for returning (relapse). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02530515 Completed - Anemia Clinical Trials

Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia

Start date: December 18, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects of ex vivo-activated autologous lymph node lymphocytes infusion and to see how well they work in treating patients with chronic lymphocytic leukemia. Biological therapies, such as ex vivo-activated autologous lymph node lymphocytes, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing.